No drugs to be had
-
https://www.medpagetoday.com/infectiousdisease/covid19/85796
The FDA has declared shortages for critical ICU sedation drugs midazolam and ketamine due to high demand for COVID-19 coronavirus patients.
Demand rose at least 51% in March for common sedatives and anesthetics used in the ICU -- propofol, dexmedetomidine, etomidate, ketamine, lorazepam, and midazolam, but the fill rate dropped to 63% before the end of the month, according to data from Vizient, the group purchasing organization for about half of U.S. acute care centers, reported by STAT.
For midazolam, the FDA's drug shortage page noted that Akorn Pharmaceuticals said it cannot supply the market demand and that Fresenius Kabi reported that it still has the drug available but is seeing increased demand. Gland Pharma and Hikma Pharmaceuticals provided little information about their shortages.
Hospira reported increased demand across midazolam products. One of its products is in limited supply and expected to be on back-order until later in April. Two others won't be ready for delivery until next June.
For ketamine, fentanyl, and lorazepam, increased demand has been cited by several companies, with only Hospira reporting that its products are in limited supply due to manufacturing delay.
